MedTrace Logo

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

NCT00557206 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2013-11-05

No results posted yet for this study

Summary

Patient receiving oxaliplatin and docetaxel will have longer progression free survival than those patients receiving standard care.

Conditions

  • Neoplasms
  • Head and Neck Neoplasms

Interventions

DRUG

Oxaliplatin and Docetaxel

Chemotherapy Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Minneapolis Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Balkrishna Jahagirdar, MD · Minneapolis Veterans Affairs Medical Center

  • Vicki A Morrison, MD · Minneapolis Veterans Affairs Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557206 on ClinicalTrials.gov